Novaliq GmbH Appoints Friedrich von Bohlen, PhD, as Chairman and Gerald Cagle, PhD, as New Member of Novaliq’s Supervisory Board
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that Friedrich von Bohlen, PhD, has been appointed Chairman of the company’s Supervisory Board and that Jerry Cagle, PhD, has joined the Board as Member.
Dr. von Bohlen has been active in the Life Sciences since 1997 and brings 20 years of entrepreneurial experience to his position. In 2005, Dr. von Bohlen co-founded dievini Hopp BioTech holding GmbH & Co KG. where he holds the position of Managing Director. Furthermore, he serves as chairman or board member of several supervisory boards that are part of the dievini portfolio. Dr. von Bohlen began his professional career in 1992 serving as a project manager in research & development at Fresenius AG. He then served as assistant to the chairman of the supervisory board of FAG Kugelfischer KGaA, and thereafter as CEO of Wasag Chemie AG. In 1997 he co-founded Lion Bioscience AG where he served as CEO until 2004 when he was named Chairman of the Board. Dr. von Bohlen holds a Diploma in Biochemistry from the University of Zurich and a PhD in Neurobiology from the Swiss Federal Institute of Technology.
Dr. Cagle began his career as an academic, serving as a faculty member of The Ohio State University in Columbus. Thereafter, and for more than three decades, he worked as a member of Alcon’s research and development team. In 1996, Dr. Cagle was named Senior Vice President of Alcon R&D and Chief Scientific Officer, a position he held until mid-2008. As head of Alcon R&D, he led the global activities of some 1,300 scientists stationed around the world. The productivity of the R&D organization, and the new products introduced during his tenure, has been recognized as a primary contributor to Alcon’s significant growth. Following his departure from Alcon, he worked on the management of Alzheimer's disease. He serves on the Board of Aerie Pharmaceuticals, Clearside Biomedical, AB2, and GrayBug. Dr. Cagle received his B.S. degree from Wayland College in Plainview, Texas, and earned both his MS and PhD degrees from the University of North Texas in Denton, Texas.
“We are pleased to have Friedrich join Novaliq as the chairman of our supervisory board. His 20 years of entrepreneurial experience is of great importance for the further prosperity of the company and especially in building a successful specialty pharma company focusing on ophthalmology,” said Mr. Günther, Novaliq’s CEO and Managing Director.
“We are delighted to have Jerry join our supervisory board. His long-term experience and vast ophthalmic knowledge is a great win for Novaliq and important for future company growth,” said Dr. Schlüter, Novaliq’s CFO and Managing Director.
“Jerry’s broad business and R&D background in this industry is an important contribution and will be crucial for Novaliq with regard to the evaluation and development of highly effective ocular therapeutics,” said Dr. von Bohlen, Chairman of Novaliq’s Supervisory Board.
“I’m excited about my new assignment as supervisory board member and look forward to being a part of Novaliq’s further development and growth. With the recent European market launch of EvoTears®, Novaliq has made a significant contribution and step forward in the treatment of dry eye disease,” said Dr. Cagle.
About Novaliq – Novaliq GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical and drug delivery company with the mission to transform poorly soluble drugs into effective ocular therapeutics for both front and back of the eye. Novaliq’s proprietary technology enhances the topical bio availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq’s most advanced product is EvoTears® with CE-marking based on Novaliq’s proprietary EyeSol® Technology. More on www.novaliq.com.
Bernhard Günther, + 49 6221 502 5911
Managing Director, CEO
Scotia Vision Consultants
Michael O’Rourke, + 1 813-323-1438
Oliver Schlüter, PhD, + 49 6221 502 59155
Managing Director, CFO
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
EUSA Pharma Announces Acquisition of Global Rights to SYLVANT® (siltuximab) from Janssen Sciences Ireland UC for $115 Million18.7.2018 06:00 | Pressemelding
EUSA Pharma (EUSA), a biopharmaceutical company focused on oncology and rare disease, announced today that it has entered into a definitive agreement with Janssen Sciences Ireland UC, a subsidiary of Janssen R&D Ireland (Janssen) to acquire the global rights to SYLVANT® (siltuximab) for $115 million in cash. The transaction is subject to review under the United States Hart–Scott–Rodino Antitrust Improvements Act of 1976, as amended, and the parties expect to close following completion of this regulatory review period and the mutual satisfaction of other remaining closing conditions. SYLVANT® is approved in more than 40 countries worldwide, including the United States, the European Union, the Republic of Korea and Canada, for the treatment of idiopathic multicentric Castleman’s disease (iMCD), a rare, life threatening and debilitating orphan condition. Idiopathic MCD is an inflammatory lymphoproliferative disorder, which causes the abnormal overgrowth of immune cells and shares many sym
The Best User Interface in Mobile and Web Tracking Just got Better18.7.2018 06:00 | Pressemelding
ThriveTracker, a leading web and mobile tracker for media buyers and performance marketers, today announced the general availability of its latest release featuring an all-new user interface (UI). Inspired by feedback from customers and partners, ThriveTracker designed the new UI to accelerate user adoption, improve usability and increase productivity. ThriveTracker focused on the user experience for all users regardless of device, (Desktop, Mobile, etc.), making it more intuitive and accessible. Improved navigation provides simplified access to frequently used functions in the platform, increases customer awareness of more advanced functionality and delivers fast access to detailed content when necessary. Cleaner, simpler, modern UI Clear, consistent navigation focuses your attention on where you are and what you can do Improved layout delivers common functions intuitively Simplified views provide faster access to relevant content Mobile Friendly Mobile responsive based on device New
JPMorgan Chase Bank announces the placement of cash-settled exchangeable bonds into Ping An Insurance (Group) Company of China Limited due 202017.7.2018 19:40 | Pressemelding
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933) OR IN OR INTO JAPAN, THE PEOPLE’S REPUBLIC OF CHINA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. JPMorgan Chase Bank, N.A. (the “Issuer”) today announces the placement of cash-settled exchangeable bonds due 2020 (the “Bonds”) in aggregate principal amount of USD 350 million. The Bonds are referable to H-shares (the “Shares”) of Ping An Insurance (Group) Company of China Limited (the “Company”). Exchange rights in respect of the Bonds will be cash-settled only. The Bonds will be issued in principal amounts of USD 200,000 and integral multiples of USD 100,000 in excess thereof and will not bear interest. The Bonds will be issued with an issue price of 100% and will redeem at par on 30 December 2020. The initial exchange price (the “Initial Exchange Price”) will
Boston Capital Announces Closing of Boston Capital Income & Value U.S. Apartment Fund17.7.2018 14:00 | Pressemelding
Boston Capital, the third largest owner of apartments in the U.S. with over $19.6 billion invested, is pleased to announce the final investor closing of Boston Capital Income and Value U.S. Apartment Fund (“BCIV”). BCIV, a discretionary multi-investor Luxembourg based fund vehicle, includes financial institutions, insurance companies, pensions, and family offices among its investors and will acquire over $350 million in apartment properties throughout the U.S. “We are very pleased to close BCIV, the latest in a succession of institutional investment vehicles through Boston Capital’s conventional apartment investment arm, Boston Capital Real Estate Partners (“BCRE”),” said Jeff Goldstein, COO and Director of Real Estate at Boston Capital. The Fund generates high current dividends and capital growth by acquiring and renovating Class B apartment properties located in major and secondary U.S. markets and by targeting a renovated rental price point well below new construction rates, which a
Amobee Wins Auction Process to Acquire Videology Assets17.7.2018 13:13 | Pressemelding
Singtel subsidiary Amobee, a leading global digital marketing technology company serving brands and agencies, today announced that it has emerged as the winner in the court supervised auction to acquire certain assets from Videology, a software provider for advanced TV and video advertising, for purchase price of approximately US$101 million1. The purchase price is subject to adjustments for accounts receivable at closing, estimated to be approximately US$20.9 million. The acquisition, following Videology’s voluntary Chapter 11 restructuring proceedings, includes Videology’s technology platform, intellectual property and certain other assets of estimated net book value of US$5.3 million2. Over the past decade, Videology has emerged as a leading provider of software that empowers advertisers and publishers to use data to optimize campaigns and spend across digital platforms and television. The addition of Videology’s capabilities will be a further boost to Amobee’s omni-channel platform
Lenovo Leaps Forward with Next-Generation ThinkAgile Composable Cloud Platform17.7.2018 12:00 | Pressemelding
Lenovo Data Center Group (HKSE: 992) (ADR: LNVGY), one of the fastest growing hyperconverged infrastructure (HCI) vendors according to IDC, – with HCI revenue growing at almost twice the market growth rate in Q1 2018 (149.1% compared to 76.3%)—is further expanding its ThinkAgile portfolio to provide an innovative solution for customers who desire the agility of the public cloud and the security of a private cloud. To address this growing customer trend, Lenovo – together with Cloudistics – has developed the ThinkAgile CP Series composable cloud platform, a ‘cloud-in-a-box’ that offers all of the conveniences and ease-of-use of a public cloud environment secured behind the customer’s own data center firewall. Lenovo ThinkAgile CP Series – with fully-integrated infrastructure, application marketplace and end-to-end automation of software-defined network, compute and storage – delivers a turnkey cloud experience that can be easily and centrally managed from anywhere through a software-as-